2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Sánchez-González, JL, Fernández-Rodríguez, EJ, Méndez-Sánchez, R, Polo-Ferrero, L, Puente-González, AS, De Ramón, C, Marcos-Asensio, S, Blázquez-Benito, P, Navarro-Bailón, A, Sánchez-Guijo, F, Martín-Sánchez, C. Effects of a strength physical exercise program in chronic lymphocytic leukemia patients on quality of life, mental health, and frailty: a randomized controlled trial study protocol. FRONT SPORTS ACT LIV 7 -. 10 mar 2025. . . F.I.: [doi:10.3389/fspor.2025.1534861]

Zugas, Ines, Tormo-Ratera, Marta, Oliver-Caldes, Aina, Soler-Perromat, Juan Carlos, Gonzalez-Calle, Veronica, Moreno, David F., Cabanas, Valentin, Lopez-Munoz, Nieves, Bartolome-Solanas, Alvaro, Espanol-Rego, Marta, Reguera-Ortega, Juan Luis, Rosinol, Laura, Lopez-Corral, Lucia, Tovar, Natalia, Rodriguez-Lobato, Luis Gerardo, Perez, Rosa Maria Alvarez, Varea, Sara, Olesti, Eulalia, Gomez-Grande, Adolfo, Frutos, Laura, Tamayo, Pilar, Juan, Manel, Moraleda, Jose M., Urbano-Ispizua, Alvaro, Gonzalez-Navarro, E. Azucena, Martinez-Lopez, Joaquin, Mateos, Maria-Victoria, Tomas, Xavier, Setoain, Xavier, de Larrea, Carlos Fernandez. Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma. BLOOD ADV 9 571-582. 11 feb 2025. . . F.I.:7,400 [doi:10.1182/bloodadvances.2024014360]
Raj, K, Eikema, DJ, Lawless, S, Koster, L, Kunadt, D, Kröger, N, Platzbecker, U, Stelljes, M, Bethge, W, Holderried, T, Fanin, R, Zeiser, R, Kuball, J, Leblond, V, Nicholson, E, Passweg, J, Potter, V, Bay, JO, Bazarbachi, A, Corral, LL, Gurnari, C, Scheid, C, Drozd-Sokolowska, J, Morris, TC, Hayden, P, Yakoub-Agha, I, Robin, M, Mclornan, DP. Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. BONE MARROW TRANSPL 60 220-226. 1 feb 2025. 1 nov 2024. . F.I.:4,500 [doi:10.1038/s41409-024-02462-5]
Zabaleta, A, Puig, N, Cedena, MT, Oliver-Caldes, A, Perez, JJ, Moreno, C, Tamariz-Amador, LE, Rodriguez-Otero, P, Prosper, F, Gonzalez-Calle, V, López-Corral, L, Rey-Búa, B, Puertas, B, Mirás, F, Sánchez-Pina, J, López-Muñoz, N, Juan, ME, González-Navarro, E, Urbano, A, de Larrea, C, Blade, J, Lahuerta, JJ, Martinez-Lopez, J, Mateos, MV, San Miguel, JF, Paiva, B. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy. AM J HEMATOL 100 93-102. 1 ene 2025. 1 nov 2024. . F.I.:10,100 [doi:10.1002/ajh.27526]

Angelillo, P, Tomas, AA, Campodonico, E, Novak, U, Gabellier, L, Blau, IW, Kwon, M, Ram, R, Forcade, E, Besley, C, Vucinic, V, Kröger, N, Corral, LL, Vydra, J, Ferrari, S, von Tresckow, B, Rubio, MT, Hernani, R, Sica, S, Stölzel, F, Rovira, M, Wagner-Drouet, E, Pérez-Simón, JA, Castilla-Llorente, C, Ferreri, AJM, Hoogenboom, JD, Ortega, IS, Malard, F, Kuball, J, Ruggeri, A. Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT. BONE MARROW TRANSPL 60 100-102. 1 ene 2025. 1 oct 2024. . F.I.:4,500 [doi:10.1038/s41409-024-02451-8]